Table 3.
AKI characteristics and evolution of the patients
| All patients (n = 52) | |
|---|---|
| AKI present at hospital admission | 8 (15.4%) |
| AKI occurrence during hospital stay | 44 (84.6%) |
| Days from hospital admission to AKI, median (IQR) | 5 (9.25) |
| Days from symptom onset to AKI, median (IQR) | 12 (8–18) |
| Pa/FIO2 at AKI, mean ± SD | 209.51 ± 94.71 |
| Mechanical ventilation (MV) | 44 (84.6%) |
| Days hospital admission MV, median (IQR) | 1 (3) |
| SOFA at AKI, mean ± SD | 8.38 ± 2.43 |
| Vasoactive drugs at AKI | 38 (73.1%) |
| Noradrenaline dose mcg/kg/min, median (IQR) | 0.19 (0.459) |
| Diuresis 24 h prior to AKI diagnosis (mL), median (IQR) | 1500 (1352) |
| Diuresis 24 h before first RRT diagnosis (mL), median (IQR) | 330 (665) |
| AKI stage at diagnosis | |
| Stage 2 | 43 (82.7%) |
| Stage 3 | 9 (17.3%) |
| Renal replacement therapy (RRT) | 15 (28.85%) |
| Days from hospital admission to first RRT, median (IQR) | 12 (11) |
| RRT days, median (IQR) | 7 (17) |
| RRT at death | 5 (9.6%) |
| Continuous renal replacement therapy (CRRT) | 13 (25%) |
| CRRT days, mean ± SD | 6.77 ± 3.56 |
| Intermittent RRT sessions, median (IQR) | 6 (3–9) |
| AKI progression from AKIN2 to AKIN3/RRT | 26 (60.46%) |
| AKI recovery | 31 (59.6%) |
| Total death | 27 (51.92%) |
| Death with AKI stage 2 | 1 (1.92%) |
| Death with AKI stage 3 | 20 (38.5%) |
| Discharged | 25 (48.08%) |
Median (IQR)/n (%)/mean ± SD
AKI acute kidney injury, RRT renal replacement therapy, CRRT continuous renal replacement therapy, IQR interquartile range, SD standard deviation, GFR glomerular filtration rate, SOFA Sequential Organ Failure Assessment score, PaFiO2 arterial blood oxygen pressure, MV mechanical ventilation